ICAM-1 in acute myocardial infarction: a potential therapeutic target.
Current treatments for AMI centre on prompt restoration of epicardial coronary blood flow. Despite improvements, AMI is still associated with significant morbidity and mortality. Novel approaches are therefore keenly sought. Intercellular adhesion molecule-1 (ICAM-1, CD54) is a member of the immunoglobulin superfamily. It is implicated in neutrophil and monocyte-endothelial cell adhesion, processes contributing to myocardial neutrophil infiltration and microvascular coronary slow flow, both viewed as important to the pathophysiologic responses in AMI. ICAM-1 would therefore appear an important potential therapeutic target in this context, and is the subject of this review.
Benson
Victoria
V
Vascular Biology Laboratory, ANZAC Medical Research Institute, Concord Repatriation General Hospital, Sydney, Australia.
McMahon
Aisling Clare
AC
Lowe
Harry Claude
HC
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000502:physiology; D015870:Gene Expression; D006801:Humans; D066298:In Vitro Techniques; D018799:Intercellular Adhesion Molecule-1 / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D009203:Myocardial Infarction / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D009504:Neutrophils / Q000502:physiology; D012995:Solubility
D000975:Antioxidants; D018799:Intercellular Adhesion Molecule-1